Welcome to our dedicated page for Day One Biopharmaceuticals news (Ticker: DAWN), a resource for investors and traders seeking the latest updates and insights on Day One Biopharmaceuticals stock.
Day One Biopharmaceuticals was a Nasdaq-listed biopharmaceutical company focused on targeted therapies for people of all ages with life-threatening diseases. News about DAWN centered on oncology product and pipeline developments, including OJEMDA (tovorafenib), an FDA-approved medicine marketed in the U.S. for pediatric low-grade glioma, and clinical-stage assets in rare cancers.
Coverage also includes the completed acquisition by Servier, related shareholder-rights and governance notices, capital-structure updates, operating and financial results, and clinical or regulatory disclosures tied to OJEMDA and other oncology programs.
Day One Biopharmaceuticals (Nasdaq: DAWN) announced its first quarter 2024 financial results and corporate progress, highlighting the launch of OJEMDA for pediatric low-grade glioma. The FDA accelerated approval of OJEMDA, the first therapy for pediatric patients with BRAF-altered pLGG. The company's cash position was $317.9 million. R&D expenses increased to $40.2 million, and G&A expenses rose to $26.6 million. Net loss was $62.4 million with upcoming events at ASCO, Goldman Sachs Conference, and ISPNO.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.